BRPI0923300A2 - "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas" - Google Patents

"derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"

Info

Publication number
BRPI0923300A2
BRPI0923300A2 BRPI0923300A BRPI0923300A BRPI0923300A2 BR PI0923300 A2 BRPI0923300 A2 BR PI0923300A2 BR PI0923300 A BRPI0923300 A BR PI0923300A BR PI0923300 A BRPI0923300 A BR PI0923300A BR PI0923300 A2 BRPI0923300 A2 BR PI0923300A2
Authority
BR
Brazil
Prior art keywords
cilostazol
vascular
treatment
metabolic diseases
nitrate derivatives
Prior art date
Application number
BRPI0923300A
Other languages
English (en)
Portuguese (pt)
Inventor
Scherhag Armin
Sartor Dirk
Original Assignee
Cardiolynx Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiolynx Ag filed Critical Cardiolynx Ag
Publication of BRPI0923300A2 publication Critical patent/BRPI0923300A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0923300A 2008-12-02 2009-12-01 "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas" BRPI0923300A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170435A EP2194048A1 (en) 2008-12-02 2008-12-02 Nitrate esters for the treatment of vascular and metabolic diseases
PCT/EP2009/066159 WO2010063724A1 (en) 2008-12-02 2009-12-01 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Publications (1)

Publication Number Publication Date
BRPI0923300A2 true BRPI0923300A2 (pt) 2019-07-16

Family

ID=40456966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923300A BRPI0923300A2 (pt) 2008-12-02 2009-12-01 "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"

Country Status (14)

Country Link
US (1) US8426597B2 (enExample)
EP (2) EP2194048A1 (enExample)
JP (1) JP2012510502A (enExample)
KR (1) KR20110088598A (enExample)
CN (1) CN102245583A (enExample)
AU (1) AU2009324123A1 (enExample)
BR (1) BRPI0923300A2 (enExample)
CA (1) CA2745252A1 (enExample)
IL (1) IL213214A0 (enExample)
MX (1) MX2011005744A (enExample)
RU (1) RU2011126607A (enExample)
SG (1) SG171423A1 (enExample)
WO (1) WO2010063724A1 (enExample)
ZA (1) ZA201104011B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525323A (ja) 2010-04-19 2013-06-20 カーディオリンクス・アーゲー 血管性及び代謝性疾患の処置のための酸化窒素ドナー担持バルサルタン誘導体
TW201204355A (en) 2010-06-02 2012-02-01 Cardiolynx Ag Nitrate derivatives of pioglitazone
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
AU2013305936B2 (en) 2012-08-21 2017-08-03 Saladax Biomedical Inc. Haptens of risperidone and paliperidone
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
PL2888258T3 (pl) 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
US9303041B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ.ベー. クエチアピンに対する抗体及びその使用
CN114044766B (zh) * 2021-10-09 2022-12-27 张北北九食品检验技术有限公司 放射性同位素碳-14标记的呋虫胺和中间体及其制备方法和应用
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
US6148496A (en) 1999-04-09 2000-11-21 The Procter & Gamble Company Method for making a seamless apertured metal belt
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
ES2299861T3 (es) 2003-07-31 2008-06-01 Nicox S.A. Derivados nitroxi de losartan y de otros bloqueadores similares del receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Also Published As

Publication number Publication date
RU2011126607A (ru) 2013-01-10
US8426597B2 (en) 2013-04-23
AU2009324123A1 (en) 2011-07-21
EP2367803A1 (en) 2011-09-28
CN102245583A (zh) 2011-11-16
JP2012510502A (ja) 2012-05-10
EP2194048A1 (en) 2010-06-09
ZA201104011B (en) 2012-02-29
IL213214A0 (en) 2011-07-31
KR20110088598A (ko) 2011-08-03
MX2011005744A (es) 2011-06-20
SG171423A1 (en) 2011-07-28
US20110230520A1 (en) 2011-09-22
CA2745252A1 (en) 2010-06-10
WO2010063724A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
MX2012002179A (es) Compuestos heterociclicos de oxima.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
NZ595189A (en) Combination therapy with thiocolchicine derivatives
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX2014003194A (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
IN2012DN00953A (enExample)
MX340577B (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2010009837A (es) Tiazolil-dihidro-indazoles.
ATE474574T1 (de) Imidazoazephinonverbindungen
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
BR112014032169A2 (pt) tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE REIVINDICADA EP 08170435.5 DE 02.12.2008 POIS NAO FOI RESPONDIDA A EXIGENCIA FORMULADA NA RPI 2518 DE 09/04/2019 SOBRE ESTA PRIORIDADE.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]